ReviewCurrent atherosclerosis reports2021
Anemia in Cardiovascular Disease: Marker of Disease Severity or Disease-modifying Therapeutic Target?
Review in Current atherosclerosis reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 31 citations in OpenAlex.
- A Predictive Model for Anemia and Coronary Heart Disease Based on Bidirectional Two-Sample Mendelian Randomization and Machine Learning.Endocrine, metabolic & immune disorders drug targets · 2026Article
- Association of Anemia with Mortality and Functional Prognosis in Patients with First-Ever Ischemic Stroke: A Retrospective Cohort Study in Tunisia.Vascular health and risk management · 2026Article
- Correlation Between Hemoglobin Levels and Severity of Coronary Artery Disease in Patients With Myocardial Infarction.Cureus · 2025Article
- Moderating Role of Anemia on the Association between Blood Urea Nitrogen and Atherosclerotic Cardiovascular Disease in Hypertension.Reviews in cardiovascular medicine · 2025Article
- Oral and Intravenous Iron Therapy.Advances in experimental medicine and biology · 2025Review
- The Dual Burden: Exploring Cardiovascular Complications in Chronic Kidney Disease.Biomolecules · 2024Review
- In blood we trust: anemia as a negative healing prognostic factor in diabetic foot patients.Acta diabetologica · 2024Article
- Relationship between HALP and PNI score with 1-month mortality after CABG.Frontiers in nutrition · 2024Article
- Understanding Arteriosclerotic Heart Disease Patients Using Electronic Health Records: A Machine Learning and Shapley Additive exPlanations Approach.Healthcare informatics research · 2023Article
- Prevalence and Risk Factors of Anemia in the MASHAD Cohort Study.Archives of Iranian medicine · 2023Article
- Deep learning-based fundus image analysis for cardiovascular disease: a review.Therapeutic advances in chronic disease · 2023Review
- Hemoglobin albumin lymphocyte and platelet score and all-cause mortality in coronary heart disease: a retrospective cohort study of NHANES database.Frontiers in cardiovascular medicine · 2023Article
- Hematologic and lymphatic system toxicities associated with immune checkpoint inhibitors: a real-world study.Frontiers in pharmacology · 2023Article
- A nomogram diagnostic cardiovascular disease in patients with erythrodermic psoriasis in Chinese.Frontiers in immunology · 2023Article
- Usefulness of Complete Blood Count (CBC) to Assess Cardiovascular and Metabolic Diseases in Clinical Settings: A Comprehensive Literature Review.Biomedicines · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purpose of the reviewIn this review paper, we examine the latest evidence regarding the use of iron supplementation, erythropoiesis-stimulating agents (ESAs), and blood transfusions as therapeutic targets for anemia to mitigate morbidity and mortality in patients with cardiovascular disease. RECENT
findingsIntravenous ferric carboxymaltose (FC) injections in heart failure (HF) have resulted in improved self-reported patient symptoms; higher exercise capacity, as measured by 6-min walk test distance in anemic patients; and lower re-hospitalization rates in iron deficient patients. Darbepoetin alfa has shown evidence of improved Kansas City Cardiomyopathy Questionnaire scores. No mortality benefits have been noted thus far with FC injections or darbepoetin in HF, with an increase in adverse events with darbepoetin. Aggressive transfusions (Hg < 10 g/dL) are not associated with improved outcomes in cardiovascular disease. Quality of life metrics, rather than mortality, appear to improve with IV FC and ESA use in HF. More studies are required to see if these treatments have a role in coronary artery disease. Current evidence suggests that anemia is a marker of underlying disease severity, with a limited role in disease modification. Further studies are required to solidify our understanding of this topic.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.